Twist Bioscience stock
Price history
+305.93% over the period1 year: from $26.46 (November 17, 2025) to $107.41 (November 17, 2026), +305.93%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $107.41 |
| October 30, 2026 | $152.78 |
| September 30, 2026 | $193.24 |
| August 31, 2026 | $139.00 |
| July 31, 2026 | $91.55 |
| June 30, 2026 | $102.88 |
| May 29, 2026 | $66.87 |
| April 30, 2026 | $58.45 |
| March 31, 2026 | $47.52 |
| February 27, 2026 | $46.92 |
| January 30, 2026 | $41.07 |
| December 31, 2025 | $31.72 |
| November 28, 2025 | $32.01 |
| November 17, 2025 | $26.46 |
At a glance
The company
Manufactures synthetic DNA-based products for therapeutics, diagnostics, chemicals, food, data storage and research applications
Latest results
Quarter to September 30, 2026 · EPS -$0.32 (estimate -$0.38)
Next event
TickerLandia's take on Twist Bioscience
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−49.02% from the 52-week high
Analysts · 13 analysts
Average target$135.17+20.68% vs. price
Buy 9 · Hold 3 · Sell 1 · Buy
TickerLandia Fingerprint: Twist Bioscience
Compared with similar companies: very high risk.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricehigh75
How much it costs relative to what it produces.
Metric Value Position in group Price/book 15.7 84 Price/sales 16.1 66 Profitabilitylow21
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 52.4% 27 ROE −19.1% 14 Operating margin −28.8% 27 ROA −9.4% 20 Net margin −28.3% 17 Earnings stabilitylow30
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 37.2% 49 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 11 Growthlow39
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +22.76% 52 Revenue growth (year over year) +27.90% 59 Earnings growth (year over year) −270.21% 6 Financial strengthhigh61
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.12 51 Current ratio 5.86 71 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong76
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −8.79% 28 Relative strength (6 months) +109.30% 99 1-year return +290.92% 100 Distance from 200-day average +12.27% 77 Riskvery high93
How much the price swings.
Metric Value Position in group Volatility (60 days) 107.5% 99 Beta (1 year) 2.95 95 Maximum drawdown (12 months) 48.8% 83
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Twist Bioscience is in line with similar companies
Twist Bioscience's Price/book: 15.7, in line with the median of a group of 9 similar companies (15.7).
Compared with 11 similar companies
| Metric | Twist Bioscience | Position in the group | Band |
|---|---|---|---|
| Operating margin | -28.8% | Low | |
| ROE | -19.1% | Low | |
| Debt/equity | 0.12 | Middle | |
| Price/book | 15.7 | Middle | |
| Net margin | -28.3% | Low |
Grey band: the middle half of the group; tick: the median; dot: Twist Bioscience. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$118.38M
Latest quarter · Q2 2026
Net income
-$35.05M
Latest quarter · Q2 2026
Quarterly net margin
-29.6%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $7.4B
- EPS
- -$2.23
- Volume
- 2.05M
- Daily trading
- €302.74M
- Dividend yield
- 0.00%
How Twist Bioscience is changing
All resultsRevenue grew 33.1% a year on average over the last 5 years
Operating margin rose from −122.3% to −36.2%
Shares outstanding up 52.6% in 5 years
Returns
Twist Bioscience returns
$1,000 invested in Twist Bioscience 5 years ago, on November 17, 2021, would be worth $926 today: −7.40% in total, −1.53% per year. This is the price return only: dividends are excluded.
| Period | Twist Bioscience | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −23.15% | −3.17% | $768 |
| 6 months | +127.78% | +0.11% | $2,278 |
| Year to date | +238.62% | +8.34% | $3,386 |
| 1 year | +305.93% | +11.15% | $4,059 |
| 3 years | +347.36% | +64.30% | $4,474 |
| 5 years | −7.40% | +58.18% | $926 |
Over the last 6 months it has done better than 99% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Twist Bioscience: technical analysis
Twist Bioscience shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 46.1% below its all-time closing high ($207.97, January 20, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 40
- Between 30 and 70
- vs 200-session average
- +19.30%
Support and resistance
Price areas where Twist Bioscience has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$117.74+5.12%2 touches, last on September 10, 2026
- Last price$112.00
- Support$83.42−25.52%4 touches, last on August 3, 2026
- Support$66.24−40.85%2 touches, last on June 9, 2026
- Support$39.07−65.12%9 touches, last on March 30, 2026
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 2.96
- Volatility (60 sessions, annualised)
- 108.2%
- Largest fall in the last year
- −48.76%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Twist Bioscience: seasonality
Average monthly price change over 8 years
Over the last 8 years, the strongest month for Twist Bioscience has been June: +23.84% on average, positive in 8 years out of 8. The weakest has been March: −6.02% on average, positive in 3 years out of 8. November, the current month, has been positive in 5 years out of 8 (+21.29% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +7.78% | +14.58% | 6 of 8 |
| February | −3.42% | −5.87% | 3 of 8 |
| March | −6.02% | −5.07% | 3 of 8 |
| April | −3.73% | −0.16% | 4 of 8 |
| May | +8.69% | +15.21% | 6 of 8 |
| June | +23.84% | +21.77% | 8 of 8 |
| July | +8.73% | +14.74% | 5 of 8 |
| August | −0.68% | −8.97% | 2 of 8 |
| September | +1.65% | −0.59% | 4 of 8 |
| October | −4.01% | −3.55% | 3 of 8 |
| November | +21.29% | +10.95% | 5 of 8 |
| December | +2.10% | −8.69% | 2 of 8 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Twist Bioscience and its competitors
Biotech and pharmaceutical developers, academic laboratories, and food, agriculture and materials companies are the customers of Twist Bioscience Corporation, which makes synthetic DNA-based products for them. Its main offer is synthetic genes and gene fragments for product development in therapeutics, diagnostics and data storage, complemented by oligo pools for CRISPR gene editing and DNA computing, and by antibody libraries. It also sells NGS library preparation kits, exome kits and custom panels, methylation detection kits for cancer research, and synthetic viral controls, including SARS-CoV-2 reference sequences.
- Headquarters
- South San Francisco, United States
- Employees
- 979
- Founded
- 2013
- Chief executive
- Emily Leproust
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Twist BioscienceTWST | $7.4B | -28.8% | — | +127.78% |
| ImmunityBioIBRX | $6.4B | -150.2% | — | −21.46% |
| Corcept TherapeuticsCORT | $9.36B | 0.8% | 190.2 | +24.30% |
| Madrigal PharmaceuticalsMDGL | $9.93B | -10.7% | — | −19.42% |
| BioMarin PharmaceuticalBMRN | $11.09B | 16.3% | 146.8 | +12.93% |
| Summit TherapeuticsSMMT | $11.32B | 0.0% | — | −36.75% |
Same industry or related industries, similar size. Compare Twist Bioscience with its competitors · Full profile
